We are hereby submitting the Notice of EGM

Kilitch Drugs (India) Ltd. KI 23" October, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Notice of Extraordinary General Meeting We would like to inform you that Extraordinary General Meeting (EGM) of the Company will be held on Monday, 16'" November, 2026, at 09:00 am (IST) through Video Conferencing or Other Audio Visual Means only. Pursuant to Regulations 30 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 (“Listing Regulations”), enclosing herewith the Notice of Extraordinary General Meeting which is being sent to those members today whose e-mail addresses are registered with the Company/ Registrar & Share Transfer Agent / Depository Participant(s), in accordance with the MCA Circulars and SEBI Circulars. A member whose name is recorded 1n the Register of Members / Register of Beneficial Owners as on the Cut-Off date i.e. Friday, 6" November, 2026 shall be entitled to avail the facility of remote e- voting / e-voting at the EGM. The remote e-Voting facility shall commence on Friday, 13 November, 2026 at 9.00 AM (IST) and will end on Sunday, 15 November, 2026 at 5.00 PM (IST). Detailed instructions pertaining to remote e-Voting are provided in the Notice of the EGM. We request you to kindly take the same on record and acknowledge the receipt. Thanking you, Yours Faithfully, For Kilitch Drugs (India) Limited Mukund Mehta Managing Director eISeO SS ree 139408051::22000038 WHO CEe RTIFIED a eR ono. Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. « Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. « CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.com « Website : www.kilitch.com Kilitch Drugs (India) Limited CIN: L24239MH1992PLC066718 Registered Office: C-301/2, M.I.D.C. TTC Industrial Area, Pawane Village, Navi Mumbai - 400 705. Tel: 022 61214100 Website: www.kilitch.com E-mail: pushpanyoupane @kilitch.com NOTICE OF EXTRA ORDINARY GENERAL MEETING Notice is hereby given that the Extra-Ordinary General Meeting (““EGM”) of the Members of Kilitch Drugs (India) Limited will be held on Monday, 16'" November, 2026, at 9:00 A.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM7”) only to transact the following business: SPECIAL BUSINESSES: 1. APPROVAL TO SELL THE ENTIRE SHAREHOLDING HELD BY THE COMPANY IN ITS MATERIAL SUBSIDIARY To consider and, if thought fit, to pass with or without modifications, the following resolution as special resolution: “RESOLVED THAT pursuant to Section 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) read with the relevant rules, notifications and circulars made thereunder, Regulation 24(5) , Regulation 37A and other applicable provisions, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (including any statutory amendment(s), modification(s) or re-enactment thereof, for the time being in force), and subject to compliance at all times to compliance with the Foreign Exchange Management Act, 1999 (including the Foreign Exchange Management (Overseas Investment) Rules, 2022, Foreign Exchange Management (Overseas Investment) Regulations, 2022) circulars, notifications and master directions issued thereunder (“FEMA”) and other applicable laws, the memorandum and the articles of association of the Company, the material subsidiary policy of the Company, approval of the board of directors of the Company and subject to obtaining all requisite consent(s), sanction(s), permission(s), clearance(s) and/or approval(s), consent of the members of the Company, be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as “Board” which shall include any committee constituted or which maybe constituted to exercise its powers including powers conferred by this resolution) to sell and transfer the entire shareholding held by the Company in Kilitch Estro Biotech PLC, a company incorporated under the laws of the Federal Democratic Republic of Ethiopia and a material subsidiary of the Company (the “Material Subsidiary”), to HarmeeCare Pharmaceuticals, a state-owned public enterprise established under the laws of the Oromia Regional State of the Federal Democratic Republic of Ethiopia (the “Buyer”), an independent buyer and not a related party, including any equity shares arising from the conversion of outstanding debt (extended by the Company to the Material Subsidiary) into equity shares of the Material Subsidiary prior to completion of the KEB Sale wherein the aggregate consideration payable by the Buyer for the sale of 100% (hundred percent) shareholding of the Material Subsidiary (and to enable the Material Subsidiary to discharge its existing debts and liabilities) shall be USD 14,000,000 (United States Dollars Fourteen Million) out of which, the consideration due to the Company shall be USD 12,855,000 (United States Dollors Twelve Million Eight Hundred and Fifty Five thousand) (“KEB Sale”), on such terms and conditions as approved by the Board of Directors of the Company in relation to the KEB Sale at such times(s) and in such form as may be decided by the Board of Directors of the Company in the best interest of the Company. RESOLVED FURTHER THAT the consent of the members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall include any committee constituted or to be constituted by the Board to exercise its powers, including the powers conferred by this resolution) to approve and finalise the binding minutes of the meeting to be executed, inter alia, amongst the Company, the Buyer and the Material Subsidiary, along with the other minority shareholders of the Material Subsidiary selling their stake, and to agree to such terms and conditions and make such modifications thereto as may be deemed necessary or expedient in the interests of the Company. RESOLVED FURTHER THAT Mr. Mukund Mehta, Managing Director, Mrs. Mira Bhavin Mehta, Managing Director and Mr. Bhavin Mukund Mehta, Whole-time Director, be and is hereby authorised, severally, to negotiate, execute and register the Minutes of the Meeting, the share purchase agreement and such other agreements, deeds, undertakings, instruments and documents as may be necessary or expedient in connection with the KEB Sale including the transition services agreement, disclosure letter, bank guarantee agreement, power of attorney and all other transaction and closing documents (collectively, the “Transaction Documents”) and all other agreements, deeds, instruments, certificates, notices and documents ancillary or incidental to the KEB Sale and to do or cause to be done all such acts, deeds, matters and things as may be necessary in connection with or incidental to the KEB Sale and the aforesaid documents, including determining the timing, manner and extent of implementation, authorising signatories, appointing and engaging advisers, consultants, agents or intermediaries, making or procuring all necessary filings, applications, disclosures, registrations and submissions, obtaining all requisite approvals, consents, permissions and clearances from the Registrar of Companies, the stock exchanges, the Securities and Exchange Board of India, the Reserve Bank of India and any other governmental, regulatory or statutory authority in any jurisdiction (including Ethiopia) and settling any questions, difficulties or doubts [Showing first 8,000 characters — download PDF for full document]